Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905210 | 0.90 | GAA (0.41) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17445853 | 0.89 | GAA (0.44) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17447430 | 0.89 | GAA (0.39) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17445854 | 0.88 | GAA (0.45) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17445855 | 0.85 | GAA (0.39) | GAAMAPTMEN1KMT2AS1PR3 | |
| SCHEMBL18910590 | 0.78 | GAA (0.41) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17447385 | 0.77 | GAA (0.44) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17438101 | 0.77 | GAA (0.46) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17445773 | 0.75 | GAA (0.50) | GAAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL17445850 | 0.75 | MAPT (0.43) | GAAALDH1A1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586890-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, UBQLN1 | GAA 630/4885ALDH1A1 2967/4885MAPT 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.